ArticleJournal of Crohn's & colitis2022
Impact of COVID-19 on Healthcare Resource Utilisation Among Patients with Inflammatory Bowel Disease in the USA.
Article in Journal of Crohn's & colitis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- The impact of COVID-19 on inflammatory bowel disease surgery: a systematic review.Annals of the Royal College of Surgeons of England · 2026Pooled it
- Trends and disparities in inflammatory bowel disease and cardiovascular disease-related mortality in the United States from 1999 to 2023: A CDC WONDER analysis.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- The Challenges in Treating Inflammatory Bowel Diseases During the COVID-19 Pandemic: An Opinion.Journal of clinical medicine · 2024Article
- The trends and outcomes of inflammatory bowel disease surgery during the COVID-19 pandemic: A retrospective propensity score-matched analysis from a multi-institutional research network.Health science reports · 2024Article
- Predictors of Hospital-related Outcomes of COVID-19 Infection in Patients With Inflammatory Bowel Disease in the Early Pandemic Phase: A Nationwide Inpatient Database Survey.Inflammatory bowel diseases · 2024Article
- Motivational Interviewing as a Strategy to Improve Adherence in IBD Treatment: An Integrative Review Amidst COVID-19 Disruptions.Healthcare (Basel, Switzerland) · 2024Review
- Excess non-COVID-19-related mortality among inflammatory bowel disease decedents during the COVID-19 pandemic.World journal of gastroenterology · 2024Article
- How Did COVID-19 Affect Mental Health and Access to Care in Persons With Inflammatory Bowel Disease.Journal of the Canadian Association of Gastroenterology · 2024Article
- Long-Term Impact of the COVID-19 Pandemic on Inflammatory Bowel Disease Healthcare Utilization: A 2-Year Nationwide Update.Inflammatory bowel diseases · 2024Article
- The Impact of COVID-19 on Health Anxiety and Perceived Stress Among Persons with IBD: A Population-representative Study.Journal of the Canadian Association of Gastroenterology · 2023Article
- The Effects of the COVID Pandemic on Patients with IBD: Lessons Learned and Future Directions.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsThe impact of the COVID-19 pandemic on patients with inflammatory bowel disease [IBD] is largely unknown. We characterised the impact of COVID-19 on IBD care by conducting an analysis of US health care claims data.
methodsWe obtained de-identified, open-source, health insurance claims data, from January 2019 to December 2020, from the Symphony Health Integrated Dataverse for US adults with IBD, and measured the rates per 1000 patients of five outcomes: colonoscopies; new biologic or small molecule treatment initiations or treatment switches; new biologic or small molecule treatment initiations or treatment switches in patients who had a colonoscopy within the previous 60 days; IBD-related surgeries; and telehealth consultations.
resultsFor 2019 and 2020, 1.32 million and 1.29 million patients with IBD, respectively, were included in the analysis. In March-April 2020, the rates of colonoscopies [17.39 vs 34.44], new biologic or small molecule treatment initiations or switches in patients who had a colonoscopy within the previous 60 days [0.76 vs 1.18], and IBD-related surgeries [2.33 vs 2.99] per 1000 patients were significantly decreased versus January-February 2020; significant year on year decreases versus 2019 were also observed. Telehealth utilisation increased in March 2020 and remained higher than in 2019 up to December 2020.
conclusionsReduction in colonoscopies and subsequent initiation/switching of treatments during the COVID-19 pandemic suggest lost opportunities for therapy optimisation which may have an impact on longer-term patient outcomes. Increased utilisation of telehealth services may have helped address gaps in routine clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.